Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but identified as OncoGenex in the filing text) on May 14, 2009. The report serves as a Regulation FD disclosure regarding the release of a press release concerning clinical trial data.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of non-financial clinical developments rather than a financial statement.
Material Changes
The material event reported is the issuance of a press release on May 14, 2009, announcing:
- The release of two ASCO (American Society of Clinical Oncology) abstracts.
- Data regarding the impact of the drug candidate OGX-011 on survival in a randomized Phase 2 trial.
- Phase 1 safety data for the drug candidate OGX-427.
Guidance, Outlook, and Risks
The filing incorporates the press release by reference but explicitly states that the information contained herein is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated. No specific financial guidance, management outlook, or risk factors are detailed within the body of this 8-K text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed clinical trial results.
- Confirm the specific survival statistics for OGX-011 and safety profiles for OGX-427 from the referenced ASCO abstracts.
- Review subsequent filings to determine if these clinical results impact the company's financial outlook or regulatory strategy.